Long Acting Injectable Buprenorphine (LAIB) has been approved for release by the Australian Therapeutic Goods Administration (TGA). Buvidal® is available from April 3 2020; Sublocade® from 21 April 2020. These pharmaceuticals exist in multiple subcutaneous formulations, to be injected either weekly or monthly, depending on the clinical assessment of patient need.
The release of LAIB - how it is prescribed and administered to patients – needs to be considered in the context of Victorian policy and regulation of Schedule 8 medicines. These considerations and other issues are discussed in this document.